Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cardiovascular Therapeutics is Scopus-indexed (Q1, CiteScore 6.1), WoS SCIE, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 1755-5914Verify ISSN ↗1755-5922Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cardiology and Cardiovascular Medicine | 92 / 409 | 77th | Q1 |
| Pharmacology (medical) | 63 / 278 | 77th | Q1 |
| Pharmacology | 101 / 328 | 69th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2008–present, best quartile Q1, CiteScore 6.1.
Cardiovascular Therapeutics is Q1 in Cardiology and Cardiovascular Medicine (rank 92 of 409), Q1 in Pharmacology (medical) (rank 63 of 278) and Q2 in Pharmacology (rank 101 of 328), by CiteScore 2025.
Cardiovascular Therapeutics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.1, which places it in quartile Q1 at the 77th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.857, quartile Q2, with an H-index of 62.
The publisher lists an article processing charge of about US$2,160 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cardiovascular Therapeutics is published by John Wiley and Sons Inc. Its print ISSN is 1755-5914 and its online ISSN is 1755-5922.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Cardiovascular Therapeutics has an h-index of 68 and a 2-year mean of 2.35 citations per paper (OpenAlex). Its Scopus CiteScore is 6.1, quartile Q1. On 2-year citations it ranks #106 of 398 Scopus journals in Cardiology and Cardiovascular Medicine.
Cardiovascular Therapeutics published 66 papers in 2025; its busiest recent year was 2017 with 79. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from China (71.7%), United States (4.3%) and Iran (2.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (1.7 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.